Exited position

Ray Dalio’s Ionis Pharmaceuticals Inc (IONS) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2021Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares67.71KHighest verified quarter-end share count
Quarters reported5Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Ionis Pharmaceuticals Inc in Q2 2021. The reported position was increased across later filings. The latest verified relationship event shows that Bridgewater Associates, LP sold the entire position in Q1 2026, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q1 2026
Sold the entire position−67.71K shares · No shares reported at quarter-end
Q4 2025
Bought 55.4% more+24.13K shares · 67.71K shares reported after the change
Filing context

Quarter-end price $79.11 · Estimated holding basis $70.30

Q3 2025
New position+43.58K shares · 43.58K shares reported
Filing context

Quarter-end price $65.42 · Estimated holding basis $65.42

Q3 2022
Sold the entire position−9.78K shares · No shares reported at quarter-end
Q2 2022
Bought 35.8% more+2.58K shares · 9.78K shares reported after the change
Filing context

Quarter-end price $37.02 · Estimated holding basis $37.06

Q1 2022
New position+7.20K shares · 7.20K shares reported
Filing context

Quarter-end price $37.08 · Estimated holding basis $37.08

Portfolio importance

How important was Ionis Pharmaceuticals Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q4 2025
Last reported rank#509of 1040 reported positions
Peak portfolio weight0.0%Q4 2025
Best historical rank#509Q4 2025
At peak importanceQ4 2025
IONS
0.0%
Largest holding
11.1%
Cross-investor discovery

Who else owns Ionis Pharmaceuticals Inc?

Also reported by 2 other tracked investors in their latest verified filings.

Cathie WoodARK Investment Management
IONS0.2% of reported portfolio
Joel GreenblattGotham Asset Management
IONS0.0% of reported portfolio
Explore Ionis Pharmaceuticals Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$44.842026-09-16

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.